Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
INGELHEIM, Germany & COPENHAGEN, Denmark--(BUSINESS WIRE)--Sep 3, 2019--
INGELHEIM, Germany & COPENHAGEN, Denmark--(BUSINESS WIRE)--Sep 3, 2019--